Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 489 entries
Sorted by: Best Match Show Resources per page
Endoplasmic reticulum stress and unfolded protein response in infection by intracellular parasites.

Future science OA

Galluzzi L, Diotallevi A, Magnani M.
PMID: 28883998
Future Sci OA. 2017 May 12;3(3):FSO198. doi: 10.4155/fsoa-2017-0020. eCollection 2017 Aug.

Perturbations of the physiological status of the endoplasmic reticulum (ER) trigger a specific response known as the ER stress response or unfolded protein response (UPR). In mammalian cells, the UPR is mediated by three ER transmembrane proteins (IRE1, PERK...

Doubling the blockade for melanoma immunotherapy.

Oncoimmunology

Galluzzi L, Eggermont A, Kroemer G.
PMID: 26942094
Oncoimmunology. 2015 Oct 29;5(1):e1106127. doi: 10.1080/2162402X.2015.1106127. eCollection 2016.

No abstract available.

Prevalence of anti-histone antibodies, their clinical significance and correlation with other autoantibodies in a cohort of Italian scleroderma patients.

Auto- immunity highlights

Morozzi G, Bellisai F, Fineschi I, Scaccia F, Pucci G, Simpatico A, Tampoia M, Chialà A, Lapadula G, Galeazzi M.
PMID: 26000117
Auto Immun Highlights. 2011 Mar 23;2(1):29-33. doi: 10.1007/s13317-011-0015-y. eCollection 2011 May.

PURPOSE: The aim of our study was to determine the prevalence, clinical significance of antibodies to individual histone components and to evaluate their correlation with other autoantibody specificities in a cohort of Italian SSc patients. Some authors, demonstrated high...

Trial watch: Naked and vectored DNA-based anticancer vaccines.

Oncoimmunology

Bloy N, Buqué A, Aranda F, Castoldi F, Eggermont A, Cremer I, Sautès-Fridman C, Fucikova J, Galon J, Spisek R, Tartour E, Zitvogel L, Kroemer G, Galluzzi L.
PMID: 26155408
Oncoimmunology. 2015 Apr 02;4(5):e1026531. doi: 10.1080/2162402X.2015.1026531. eCollection 2015 May.

One type of anticancer vaccine relies on the administration of DNA constructs encoding one or multiple tumor-associated antigens (TAAs). The ultimate objective of these preparations, which can be naked or vectored by non-pathogenic viruses, bacteria or yeast cells, is...

Combinatorial immunotherapy with checkpoint blockers solves the problem of metastatic melanoma-An exclamation sign with a question mark.

Oncoimmunology

Kroemer G, Galluzzi L.
PMID: 26140249
Oncoimmunology. 2015 Jun 03;4(7):e1058037. doi: 10.1080/2162402X.2015.1058037. eCollection 2015 Jul.

Results from recent clinical trials demonstrate that a combinatorial immunotherapeutic regimen based on 2 distinct checkpoint blockers, namely, the CTLA4-targeting agent ipilimumab and the PD-1-specific molecule nivolumab, causes objective responses in a majority of subjects with advanced melanoma. These...

Colorectal cancer: the first neoplasia found to be under immunosurveillance and the last one to respond to immunotherapy?.

Oncoimmunology

Kroemer G, Galluzzi L, Zitvogel L, Fridman WH.
PMID: 26140250
Oncoimmunology. 2015 Jun 05;4(7):e1058597. doi: 10.1080/2162402X.2015.1058597. eCollection 2015 Jul.

The first study demonstrating that human colorectal carcinoma (CRC) is under robust immunosurveillance was published a decade ago. Today, it is clear that CRC patients with Stage III lesions abundantly infiltrated by effector memory T cells have a better...

Magnetic Resonance Enterography Findings of Intestinal Behçet Disease in a Child.

Case reports in radiology

D'Angelo T, Gallizzi R, Romano C, Cicero G, Mazziotti S.
PMID: 28630777
Case Rep Radiol. 2017;2017:8061648. doi: 10.1155/2017/8061648. Epub 2017 May 24.

Behçet's disease (BD) is a multisystem disorder of unknown aetiology, characterized by recurrent oral ulcers, genital ulcers, uveitis, skin lesions, and pathergy. Gastrointestinal disease outside the oral cavity is well recognized and usually takes the form of small intestinal...

Trial watch: Tumor-targeting monoclonal antibodies for oncological indications.

Oncoimmunology

Vacchelli E, Pol J, Bloy N, Eggermont A, Cremer I, Fridman WH, Galon J, Marabelle A, Kohrt H, Zitvogel L, Kroemer G, Galluzzi L.
PMID: 25949870
Oncoimmunology. 2015 Feb 03;4(1):e985940. doi: 10.4161/2162402X.2014.985940. eCollection 2015 Jan.

An expanding panel of monoclonal antibodies (mAbs) that specifically target malignant cells or intercept trophic factors delivered by the tumor stroma is now available for cancer therapy. These mAbs can exert direct antiproliferative/cytotoxic effects as they inhibit pro-survival signal...

Fermi-LAT observations of the gamma-ray burst GRB 130427A.

Science (New York, N.Y.)

Ackermann M, Ajello M, Asano K, Atwood WB, Axelsson M, Baldini L, Ballet J, Barbiellini G, Baring MG, Bastieri D, Bechtol K, Bellazzini R, Bissaldi E, Bonamente E, Bregeon J, Brigida M, Bruel P, Buehler R, Burgess JM, Buson S, Caliandro GA, Cameron RA, Caraveo PA, Cecchi C, Chaplin V, Charles E, Chekhtman A, Cheung CC, Chiang J, Chiaro G, Ciprini S, Claus R, Cleveland W, Cohen-Tanugi J, Collazzi A, Cominsky LR, Connaughton V, Conrad J, Cutini S, D'Ammando F, de Angelis A, DeKlotz M, de Palma F, Dermer CD, Desiante R, Diekmann A, Di Venere L, Drell PS, Drlica-Wagner A, Favuzzi C, Fegan SJ, Ferrara EC, Finke J, Fitzpatrick G, Focke WB, Franckowiak A, Fukazawa Y, Funk S, Fusco P, Gargano F, Gehrels N, Germani S, Gibby M, Giglietto N, Giles M, Giordano F, Giroletti M, Godfrey G, Granot J, Grenier IA, Grove JE, Gruber D, Guiriec S, Hadasch D, Hanabata Y, Harding AK, Hayashida M, Hays E, Horan D, Hughes RE, Inoue Y, Jogler T, Jóhannesson G, Johnson WN, Kawano T, Knödlseder J, Kocevski D, Kuss M, Lande J, Larsson S, Latronico L, Longo F, Loparco F, Lovellette MN, Lubrano P, Mayer M, Mazziotta MN, McEnery JE, Michelson PF, Mizuno T, Moiseev AA, Monzani ME, Moretti E, Morselli A, Moskalenko IV, Murgia S, Nemmen R, Nuss E, Ohno M, Ohsugi T, Okumura A, Omodei N, Orienti M, Paneque D, Pelassa V, Perkins JS, Pesce-Rollins M, Petrosian V, Piron F, Pivato G, Porter TA, Racusin JL, Rainò S, Rando R, Razzano M, Razzaque S, Reimer A, Reimer O, Ritz S, Roth M, Ryde F, Sartori A, Parkinson PM, Scargle JD, Schulz A, Sgrò C, Siskind EJ, Sonbas E, Spandre G, Spinelli P, Tajima H, Takahashi H, Thayer JG, Thayer JB, Thompson DJ, Tibaldo L, Tinivella M, Torres DF, Tosti G, Troja E, Usher TL, Vandenbroucke J, Vasileiou V, Vianello G, Vitale V, Winer BL, Wood KS, Yamazaki R, Younes G, Yu HF, Zhu SJ, Bhat PN, Briggs MS, Byrne D, Foley S, Goldstein A, Jenke P, Kippen RM, Kouveliotou C, McBreen S, Meegan C, Paciesas WS, Preece R, Rau A, Tierney D, van der Horst AJ, von Kienlin A, Wilson-Hodge C, Xiong S, Cusumano G, La Parola V, Cummings JR.
PMID: 24263133
Science. 2014 Jan 03;343(6166):42-7. doi: 10.1126/science.1242353. Epub 2013 Nov 21.

The observations of the exceptionally bright gamma-ray burst (GRB) 130427A by the Large Area Telescope aboard the Fermi Gamma-ray Space Telescope provide constraints on the nature of these unique astrophysical sources. GRB 130427A had the largest fluence, highest-energy photon...

Disease Activity and Bone Mineral Density of MCP Joints in Patients with Rheumatoid and Psoriatic Arthritis: Is There a Correlation?-A Study in Patients Treated with Methotrexate and an Anti-TNF α Agent.

ISRN rheumatology

Bertoldi I, Filippou G, Scirè CA, Picerno V, di Sabatino V, Adinolfi A, Pierguidi S, Galeazzi M, Frediani B.
PMID: 24381766
ISRN Rheumatol. 2013 Dec 07;2013:708323. doi: 10.1155/2013/708323. eCollection 2013.

Background. Bone damage in rheumatoid arthritis (RA) and in psoriatic arthritis (PsA) includes an accelerated bone mineral density (BMD) reduction. The objective was to evaluate BMD variations of the metacarpophalangeal joints (MCPs) in patients starting treatment with methotrexate (MTX)...

ANTIBIOTIC-LOADED REGENOSS FOR THE TREATMENT OF SEPTIC BONE DEFECTS: IN VITRO STUDY AND PRELIMINARY CLINICAL EXPERIENCE.

Journal of biological regulators and homeostatic agents

Romano' CL, Gallazzi E, Logoluso N, De Vecchi E, Drago L.
PMID: 26652496
J Biol Regul Homeost Agents. 2015 Oct-Dec;29(4):103-10.

Bone and joint infections are a difficult to treat condition, often associated with bone loss. Although the management of septic bone defects may currently be achieved through various treatment modalities, there is a continuous need for bone substitutes able...

Trial watch: Dendritic cell-based anticancer therapy.

Oncoimmunology

Bloy N, Pol J, Aranda F, Eggermont A, Cremer I, Fridman WH, Fučíková J, Galon J, Tartour E, Spisek R, Dhodapkar MV, Zitvogel L, Kroemer G, Galluzzi L.
PMID: 25941593
Oncoimmunology. 2014 Dec 21;3(11):e963424. doi: 10.4161/21624011.2014.963424. eCollection 2014 Nov.

The use of patient-derived dendritic cells (DCs) as a means to elicit therapeutically relevant immune responses in cancer patients has been extensively investigated throughout the past decade. In this context, DCs are generally expanded, exposed to autologous tumor cell...

Showing 1 to 12 of 489 entries